טוען...
Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor
ERBB3/HER3 expression and signaling is upregulated in mutant BRAF melanoma as an adaptive, pro-survival response to FDA-approved RAF inhibitors. Since compensatory ERBB3 signaling counteracts the effects of RAF inhibitors, co-targeting ERBB3 may increase the efficacy of RAF inhibitors in mutant BRAF...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4120074/ https://ncbi.nlm.nih.gov/pubmed/25035390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-0464 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|